For Immediate Release
Chicago, IL – September 4, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Bristol-Myers Squibb (BMY - Free Report) , Qualcomm (QCOM - Free Report) , Citigroup (C - Free Report) , Diageo (DEO - Free Report) and Anthem (ANTM - Free Report) .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Bristol-Myers, Qualcomm and Citigroup
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers Squibb, Qualcomm and Citigroup. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of buy-rated Bristol-Myers have underperformed the Zacks Large Cap Pharmaceuticals industry in the last six months, losing -7.6% vs. a gain of -7.9%. However, Bristol-Myers' blockbuster immuno-oncology drug Opdivo continues to maintain momentum.
Opdivo’s performance is being boosted by the uptake in new indications, first line renal cell and adjuvant melanoma. Several label expansion applications for Opdivo are under review in the United States and Europe. The drug was recently approved for small cell lung cancer in the United States and melanoma in Europe.
Potential approval in other indications will further boost the prospects of this blockbuster drug. Eliquis is expected to drive further growth in 2018 driven by increases in market share in the novel oral anticoagulant (NOAC) market.
The label expansion of other drugs like Sprycel and Empliciti also bode well for the company. However, pricing concerns, stiff competition in the immuno-oncology space are expected to remain an overhang.
(You can read the full research report on Bristol-Myers here >>>).
Buy-rated Qualcomm’s shares have gained +30.9% over the past one year vs +23.8% for the Zacks Wireless Equipment industry as it remains focused on $1 billion cost-cut plan. Qualcomm has been trying to retain its leadership in 5G, chipset market and mobile connectivity with multiple technological achievements and innovative product launches.
The company’s improved and upgraded technologies will likely enable various firms to build new and updated products and services across the wireless ecosystem to better serve customers. Qualcomm aborted the proposed acquisition of NXP Semiconductors as it failed to get the anti-trust approval from China, thereby eliminating the uncertainty with the deal stuck in red tape for 21 months.
This is likely to pave the path for focused organic growth of the company. However, regulatory disputes and aggressive competition in the mobile phone chipset market continue to hurt Qualcomm. Headwinds from weaker industry conditions have further dented margins.
(You can read the full research report on Qualcomm here >>>).
Shares of Citigroup have underperformed the Zacks Banks - Major Regional industry over the last six months (-3% vs. 1.2%). Yet, the company possesses an impressive earnings surprise history, beating the Zacks Consensus Estimate in all the trailing four quarters.
The Zacks analyst believes the company’s restructuring and streamlining efforts, strategic investments in core business, lower tax rate and expense management will likely support profitability. Recently, the capital plan approval reflects strong capital position.
Yet, several issues, including litigation burden, keep the analyst apprehensive. Also, despite rising rates, margin remains under pressure, due to persistent decline in the company’s legacy holdings portfolio.
(You can read the full research report on Citigroup here >>>).
Other noteworthy reports we are featuring today include Diageo and Anthem.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market.
Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.